News

Hospital readmission risk in pediatric patients was higher in those who were first admitted for RSV than in those who were first admitted for influenza or hMPV.
The FDA has accepted for review the sBLA to expand the indication of Arexvy (RSV vaccine, adjuvanted) to adults aged 18 to 49 years who are at increased risk.
A new CHOP study found only one in three eligible patients took Beyfortus when the medication that protects against severe ...
“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...